Confo Therapeutics products

G protein-coupled receptors (GPCRs) are the largest and most diverse group of membrane receptors in the body. They play a key role in a broad range of biological processes by binding to a wide variety of signaling molecules, yet they share a common architecture. GPCRs are comprised of seven transmembrane (TM) helices that span the cell membrane and intervening loops that are presented towards either the extracellular (EC) or intracellular (IC) environments. Agonists bind to GPCRs at an EC-facing binding pocket and initiate conformational changes that are propagated to the IC loops. This subsequently triggers downstream signaling via G-proteins or G-protein-independent pathways.

With its unique antibody-based technology, Confo Therapeutics aims to overcome the current limitations of GPCR drug discovery in order to fully realize the potential of GPCRs as drug targets.

Confo Therapeutics is building a pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments.